The FDA is busy busting up drug counterfeiting rings—but is it doing enough to protect patients?news2022-05-26T19:19:57+00:00May 26th, 2022|Fierce Pharma|
‘The Top Line’ podcast: How biopharma is tackling the monkeypox outbreak, insight on nominations for our Fierce 15 list, plus this week’s headlinesnews2022-05-26T18:15:35+00:00May 26th, 2022|Fierce Pharma|
ASCO: Bristol Myers delves into Opdualag’s LAG-3 melanoma win in key populationsnews2022-05-26T16:18:40+00:00May 26th, 2022|Fierce Pharma|
Sanofi, Regeneron’s Libtayo scores UK watchdog’s approval in common form of skin cancernews2022-05-26T15:02:34+00:00May 26th, 2022|Fierce Pharma|
ASCO: Merck touts Keytruda’s ‘convergent’ benefits across postsurgery lung cancer patient groupsnews2022-05-26T14:34:47+00:00May 26th, 2022|Fierce Pharma|
Servier’s Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancernews2022-05-26T14:03:34+00:00May 26th, 2022|Fierce Pharma|
Pfizer antiviral usage is ticking up in the US as uptake of Merck, AZ drugs remains limitednews2022-05-26T14:00:09+00:00May 26th, 2022|Fierce Pharma|
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia datanews2022-05-26T09:35:42+00:00May 26th, 2022|Fierce Pharma|
Eli Lilly plots $2.1B manufacturing expansion at America’s crossroads, with 500 new hiresnews2022-05-25T17:48:23+00:00May 25th, 2022|Fierce Pharma|
ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult populationnews2022-05-25T16:14:56+00:00May 25th, 2022|Fierce Pharma|
